Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2025-04-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普莱柯生物工程股份有限公司 regarding the receipt of a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs. It details the new drug's name, classification, components, indications, and development background. The document is short (1080 characters) and serves as an official announcement of a regulatory approval event rather than a detailed report or financial filing. It does not contain financial data, management discussion, or detailed regulatory filings but is a formal disclosure of a new product registration certificate. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-28 Chinese
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company 普莱柯生物工程股份有限公司 regarding the receipt of a new veterinary drug registration certificate issued by the Ministry of Agriculture and Rural Affairs of China. It details the new drug's name, classification, development background, and the impact on the company. The document is short (933 characters) and serves as a formal public notice about a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category about compliance and approvals. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-04-28 Chinese
普莱柯2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting as of December 31, 2024. The document contains an auditor's opinion on the effectiveness of internal controls, issued by a registered accounting firm. The length is 1321 characters, which is relatively short but contains the full audit opinion text rather than just an announcement. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) or Interim Report (IR) because it focuses solely on internal control audit opinion, not full financial statements or comprehensive financial performance. It is not a Regulatory Filing (RNS) because it contains substantive audit opinion content, not just certification or attestation. Therefore, the correct classification is AR with high confidence.
2025-04-24 Chinese
普莱柯关于召开2024年度暨2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an investor performance explanation meeting (业绩说明会) for the 2024 annual and 2025 first quarter results. It provides details on the meeting time, location, format, and participation instructions. It references that the 2024 annual report and 2025 first quarter report have already been published on April 24, 2025, but this document itself is not the report or transcript. The document is short (1482 characters) and serves as a notice for an upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or a meeting notice. Given the detailed meeting information and focus on investor communication, the classification is Investor Presentation (IP).
2025-04-24 Chinese
普莱柯关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of 普莱柯生物工程股份有限公司, including the date, voting methods, agenda items, and proxy voting instructions. It does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The document length is 4236 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on meeting logistics, agenda, and voting instructions, which aligns with the definition of AGM Information (AGM-R).
2025-04-24 Chinese
华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金及部分募投项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Huatai United Securities regarding the verification and review of certain fundraising projects of Pulike Bioengineering Co., Ltd. It discusses the use of proceeds from a non-public issuance of A shares, including project completion, surplus funds being permanently added to working capital, and project delays. The document includes financial figures related to fundraising, project investment, and usage, as well as approvals from the board and supervisory committee. It is a formal verification opinion related to fundraising projects and their management, not a general financial report or earnings release. It is not a brief announcement but a substantive report on fundraising project status and compliance with regulatory requirements. This fits the category of Capital/Financing Update (CAP), as it deals with fundraising usage and capital allocation updates.
2025-04-24 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.